FBRX Forte Biosciences, Inc.
Price Chart
Executive Summary
Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended and restated 2021 Equity Incentive Plan (adding 1,850,000 new shares for a total reserve of 5,190,000 shares) and re-elected three Class III directors. The filing is a routine governance update with no material financial data or operational changes.
Actionable Insight
Routine annual meeting filing with no earnings or operational news. The equity plan approval enables future equity grants but does not trigger immediate dilution. Monitor for subsequent option grants or S-8 filings that would indicate actual share issuance.
Key Facts
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 11,911,879 votes for, 3,997,050 against, and 351,042 abstentions.
- The plan reserves 5,190,000 shares total, including 1,850,000 newly requested shares.
- Three Class III directors (Steven Kornfeld, Scott Brun, Paul A. Wagner) were re-elected.
- KPMG LLP was ratified as independent auditor for FY2026 with 17,722,893 votes for.
- Advisory vote on executive compensation passed with 12,143,153 votes for.
- No officer departures, no financial results, and no guidance were reported.
Financial Impact
No financial figures reported; the equity plan adds 1,850,000 new shares to the reserve, representing potential future dilution of approximately 9% of the 20,478,817 shares outstanding.
Risk Factors
- Potential future dilution from equity awards under the approved plan.
- No cross-filing context provided; no other corporate events to assess.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253436 |
| Document: d110060d8k.htm | 0001193125-26-253436 |
| Document: 0001193125-26-253436-index-headers.html | 0001193125-26-253436 |
| Document: 0001193125-26-253436-index.html | 0001193125-26-253436 |
| Document: 0001193125-26-253436.txt | 0001193125-26-253436 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
EFFECT
| $16.86 awaiting T+1 | awaiting T+1 | — | $17.56 (−4.15%) |
|
Jun 6, 2026
7d ago
|
S-3/A
| $16.37 awaiting T+1 | awaiting T+1 | — | $17.56 (−7.27%) |
|
Jun 2, 2026
10d ago
|
S-3
| $17.00 $16.69 | ▲ +1.82% | ▲ +2.22% | $17.56 (−3.29%) |
|
Jun 2, 2026
10d ago
|
8-K
| $17.00 $16.69 | ▼ −1.82% | ▼ −2.23% | $17.56 (+3.29%) |
|
May 14, 2026
29d ago
|
8-K
| $23.11 $20.97 | ▼ −9.26% | ▼ −9.20% | $17.56 (−24.02%) |
|
Apr 9, 2026
9w ago
|
8-K
| $33.90 $35.09 | ▲ +3.51% | ▲ +3.57% | $17.56 (−48.20%) |
|
Apr 8, 2026
9w ago
|
424B5
| $33.90 $35.09 | ▼ −3.51% | ▼ −3.57% | $17.56 (+48.20%) |
|
Apr 1, 2026
10w ago
|
8-K
| $24.86 $25.58 | ▼ −2.90% | ▼ −2.82% | $17.56 (+29.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access